TBPH

15.22

3.82% 0.56

Vorhandelsmarkt: 14.85 -0.37 -2.43%

Theravance Biopharma Inc (TBPH)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$14.66

Offen:

$14.75

24-Stunden-Volumen:

673.10K

Relative Volume:

1.67

Marktkapitalisierung:

$766.50M

Einnahmen:

$62.02M

Nettoeinkommen (Verlust:

$-45.65M

KGV:

-16.54

EPS:

-0.92

Netto-Cashflow:

$-9.60M

1W Leistung:

+6.43%

1M Leistung:

+5.62%

6M Leistung:

+46.77%

1J Leistung:

+83.82%

1-Tages-Spanne:

$14.46

$15.34

1-Wochen-Bereich:

$13.95

$15.34

52-Wochen-Spanne:

$7.90

$15.34

Theravance Biopharma Inc Stock (TBPH) Company Profile

Firmenname

Theravance Biopharma Inc

Sektor

Healthcare (1136)

Branche

Biotechnology (633)

Telefon

650-808-6000

Adresse

UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-12

Neueste SEC-Einreichungen

TBPH's Discussions on Twitter

Vergleichen Sie TBPH mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TBPH Theravance Biopharma Inc	15.22	738.30M	62.02M	-45.65M	-9.60M	-0.92
VRTX Vertex Pharmaceuticals Inc	426.00	109.11B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	642.25	68.50B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	434.07	60.25B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	826.28	50.39B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	186.23	40.44B	447.02M	-1.18B	-868.57M	-6.1812

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-09-12	Eingeleitet	B. Riley Securities	Buy
2024-08-06	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-04-12	Eingeleitet	BTIG Research	Buy
2024-01-08	Herabstufung	Evercore ISI	Outperform → In-line
2022-05-23	Eingeleitet	SVB Leerink	Outperform
2021-11-05	Hochstufung	JP Morgan	Underweight → Neutral
2021-09-15	Herabstufung	JP Morgan	Overweight → Underweight
2021-08-25	Herabstufung	Morgan Stanley	Overweight → Underweight
2021-08-24	Herabstufung	Cowen	Outperform → Market Perform
2020-10-14	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-07-07	Eingeleitet	JP Morgan	Overweight
2020-06-15	Eingeleitet	Morgan Stanley	Equal-Weight
2020-05-13	Eingeleitet	Cowen	Outperform
2020-01-08	Bestätigt	H.C. Wainwright	Buy
2019-11-06	Hochstufung	Robert W. Baird	Underperform → Neutral
2019-10-29	Eingeleitet	H.C. Wainwright	Buy
2018-03-29	Fortgesetzt	Piper Jaffray	Overweight
2017-08-17	Eingeleitet	Evercore ISI	Outperform
2017-06-16	Eingeleitet	Cantor Fitzgerald	Overweight
2017-05-11	Bestätigt	Needham	Buy
2016-12-21	Eingeleitet	Needham	Buy
2016-11-03	Eingeleitet	Piper Jaffray	Overweight
2016-10-12	Herabstufung	Robert W. Baird	Neutral → Underperform
2016-08-03	Herabstufung	BofA/Merrill	Neutral → Underperform
2016-06-20	Eingeleitet	Guggenheim	Buy
2016-06-20	Bestätigt	Leerink Partners	Outperform
2016-05-12	Eingeleitet	Leerink Partners	Outperform
2016-05-05	Herabstufung	BofA/Merrill	Buy → Neutral
2015-02-03	Hochstufung	Robert W. Baird	Underperform → Neutral

Alle ansehen

Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten

02:47 AM

Can Theravance Biopharma Inc. (0TB) stock sustain revenue momentumMarket Risk Analysis & Fast Moving Trade Plans - newser.com

02:47 AM

Nov 03, 2025

Can Theravance Biopharma Inc. stock attract ESG capital inflowsPortfolio Risk Report & Reliable Price Action Trade Plans - newser.com

Nov 03, 2025

Can Theravance Biopharma Inc. stock maintain operating margins2025 Stock Rankings & Weekly High Return Stock Opportunities - newser.com

Nov 03, 2025

News impact scoring models applied to Theravance Biopharma Inc.2025 Year in Review & Free Community Consensus Stock Picks - newser.com

Nov 03, 2025

Is Theravance Biopharma Inc. stock cheap at current valuationWeekly Stock Summary & Community Driven Trade Alerts - newser.com

Nov 03, 2025

Why Theravance Biopharma Inc. stock is in analyst buy zone2025 Technical Patterns & Technical Confirmation Alerts - newser.com

Nov 03, 2025

Comparing Theravance Biopharma Inc. in custom built stock radarsRate Hike & Consistent Income Trade Ideas - newser.com

Nov 03, 2025

Will a bounce in Theravance Biopharma Inc. offer an exitQuarterly Profit Review & Capital Efficiency Focused Strategies - newser.com

Nov 03, 2025

Theravance Biopharma Inc. stock retracement – recovery analysisEntry Point & Free AI Powered Buy and Sell Recommendations - newser.com

Nov 03, 2025

What consensus target says about Theravance Biopharma Inc. (0TB) stockInflation Watch & Verified Short-Term Trading Plans - newser.com

Nov 03, 2025

Is Theravance Biopharma Inc. (0TB) stock a momentum leaderTreasury Yields & Safe Capital Growth Tips - newser.com

Nov 03, 2025

Can Theravance Biopharma Inc. stock deliver consistent earnings growthJuly 2025 Sentiment & Stepwise Trade Execution Plans - newser.com

Nov 03, 2025

Nov 02, 2025

What to expect from Theravance Biopharma Inc. in the next 30 daysJuly 2025 PostEarnings & Real-Time Volume Analysis - newser.com

Nov 02, 2025

Can Theravance Biopharma Inc. (0TB) stock hit consensus price targets2025 Price Targets & Safe Entry Trade Signal Reports - newser.com

Nov 02, 2025

Why Theravance Biopharma Inc. (0TB) stock benefits from AI revolutionMarket Performance Recap & Reliable Breakout Forecasts - newser.com

Nov 02, 2025

Why Theravance Biopharma Inc. (0TB) stock remains stableJuly 2025 Sentiment & Fast Exit Strategy with Risk Control - newser.com

Nov 02, 2025

Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

Nov 02, 2025

Theravance Biopharma Inc. stock trendline breakdownJuly 2025 PostEarnings & Real-Time Buy Zone Alerts - newser.com

Nov 02, 2025

Will Theravance Biopharma Inc. stock see insider buyingAnalyst Upgrade & Technical Pattern Based Signals - newser.com

Nov 02, 2025

Oct 31, 2025

How to escape a deep drawdown in Theravance Biopharma Inc.July 2025 Intraday Action & Capital Efficient Trading Techniques - newser.com

Oct 31, 2025

Oct 30, 2025